MOv18 monoclonal antibody in diagnostic applications: capability to recognize the histotype of the original tumor.
Cells from 52 ascitic fluids and 28 abdominopelvic cavity washings, obtained from 46 ovarian cancer patients, 17 patients bearing malignancies of non ovarian sites and 17 patients with non-malignant ovarian diseases, were tested using 2 methods: traditional cytology and monoclonal antibody immunofluorescence. The immunologic test using the MOv18 MAb, raised against ovarian carcinoma, revealed immunoreactive cells in 83% of the 36 cytologically positive fluids and in one of the 8 negative fluids from ovarian carcinoma patients and in 18% of the 17 fluids from patients with non-malignant ovarian disease. Forty six cytologically positive ascitic fluids from malignant patients were analyzed in order to evaluate the ability of this MAb to identify the histotype of metastatic cells. Ninety-three percent (26/28) of the effusions from nonmucinous ovarian carcinomas contained MOv18-positive cells, whereas no reactive cells were found in cytologically malignant fluids from patients with ovarian tumors of other oncotypes or with carcinomas of non-ovarian origin. The MOv18 reagent, used as an adjuvant in cytological analysis, can help in the identification of the histotype of metastatic cells of unknown origin.
Belloni
C
C
IV Clinica Ostetrica Ginecologica, Università di Milano, Italy.
Bianchi
M C
MC
Colombo
G
G
Frigerio
A
A
Luchini
S
S
Ménard
S
S
Pizzetti
P
P
Taccagni
G L
GL
Tagliabue
E
E
Colnaghi
M I
MI
D000230:Adenocarcinoma / Q000175:diagnosis; D000911:Antibodies, Monoclonal; D003581:Cytodiagnosis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000175:diagnosis*
D000911:Antibodies, Monoclonal